<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140047</url>
  </required_header>
  <id_info>
    <org_study_id>MT-2301-J01</org_study_id>
    <nct_id>NCT02140047</nct_id>
  </id_info>
  <brief_title>Exploratory Clinical Study of MT-2301</brief_title>
  <official_title>Exploratory Clinical Study of MT-2301 in Healthy Infants (Phase 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate efficacy and safety of MT-2301 when co-administered
      with DPT-IPV using ActHIB® as a control in healthy infants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-PRP antibody prevalence rate with 1 μg/mL or higher</measure>
    <time_frame>4 weeks after the primary immunization (Visit 4)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anti-PRP antibody prevalence rate with 0.15 μg/mL or higher</measure>
    <time_frame>4 weeks after the primary immunization (Visit 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean antibody titer (GMT) of anti-PRP antibody</measure>
    <time_frame>4 weeks after the primary immunization (Visit 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PRP antibody prevalence rate with 1 μg/mL or higher</measure>
    <time_frame>4 weeks after the booster dose (Visit 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-PRP antibody prevalence rate with 0.15 μg/mL or higher</measure>
    <time_frame>4 weeks after the booster dose (Visit 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric mean antibody titer (GMT) of anti-PRP antibody</measure>
    <time_frame>4 weeks after the booster dose (Visit 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody prevalence rate and geometric mean antibody titer (GMT) against diphtheria toxin, pertussis, tetanus toxin, and less virulent strain of polio virus</measure>
    <time_frame>4 weeks after the primary immunization (Visit 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody prevalence rate and geometric mean antibody titer (GMT) against diphtheria toxin, pertussis, tetanus toxin, and less virulent strain of polio virus</measure>
    <time_frame>4 weeks after the booster dose (Visit 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and adverse reactions</measure>
    <time_frame>through the first dose (Visit 1) to 4 weeks after the booster dose (Visit 6)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Haemophilus Influenza Type b</condition>
  <arm_group>
    <arm_group_label>MT-2301-Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MT-2301-High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ActHib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV</intervention_name>
    <description>0.25mL, subcutaneous injection</description>
    <arm_group_label>MT-2301-Low</arm_group_label>
    <other_name>MT-2301-Low + Tetrabik®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV</intervention_name>
    <description>0.5mL, subcutaneous injection</description>
    <arm_group_label>MT-2301-High</arm_group_label>
    <other_name>MT-2301-High + Tetrabik®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Haemophilus influenza type b conjugate vaccine + DPT-IPV</intervention_name>
    <description>0.5mL, subcutaneous injection</description>
    <arm_group_label>ActHib</arm_group_label>
    <other_name>ActHib® + Tetrabik®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy infants aged ≥2 and &lt;7 months at the first vaccination of the study drug

          -  Written informed consent is obtained from a legal guardian (parent)

        Exclusion Criteria:

          -  With obvious pyrexia (axillary temperature of 37.5ºC or higher) at vaccination of the
             study drug

          -  With known serious acute disease

          -  With known underlying disease such as cardiovascular disease, renal disease, hepatic
             disease, blood dyscrasia, and respiratory disease

          -  With past diagnosis of immunodeficiency or currently under immunosuppressive treatment

          -  History of anaphylaxis due to food or pharmaceuticals

          -  With experience of Hib infection, diphtheria, pertussis, tetanus, and acute
             poliomyelitis

          -  With experience of Hib vaccination, or administration of vaccine including either
             diphtheria, pertussis, tetanus, or polio as a constituent

          -  History of convulsions

          -  Administered a live vaccine within 27 days before the first vaccination of the study
             drug, or inactivated vaccine or toxoid within 6 days before vaccination

          -  Administered transfusion, immunosuppressant (excluding drugs for external use), or
             immunoglobulin formulation

          -  Administered corticosteroid 2 mg/kg per day or more as prednisolone (excluding drugs
             for external use) continuously for more than 1 week

          -  Participated in other studies within 12 weeks before obtaining consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>7 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takashi Nakano, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Department of pediatrics, Kawasaki Hospital, Kawasaki Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational site</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <last_update_submitted>October 15, 2015</last_update_submitted>
  <last_update_submitted_qc>October 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Haemophilus influenza type b</keyword>
  <keyword>Hib</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

